Welcome to our dedicated page for Cardiff Oncology SEC filings (Ticker: CRDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardiff Oncology, Inc. filings document regulatory disclosures for a clinical-stage oncology company developing onvansertib and PLK1-inhibition programs. Recent Form 8-K reports cover financial results, business updates, Regulation FD presentation materials, CRDF-004 clinical disclosures in first-line RAS-mutated metastatic colorectal cancer and other material events tied to the company's development strategy.
The company's proxy and current reports also address board and executive governance, officer appointments and departures, separation agreements, compensation arrangements, equity awards and Nasdaq inducement grants. These filings include formal disclosure of risk themes common to clinical-stage biotechnology issuers, including clinical-trial uncertainty, financing needs, dependence on key personnel and operating disruptions.
Cardiff Oncology CEO Mani Mohindru reported an open-market purchase of 24,703 shares of Common Stock at $1.21 per share. This transaction took place on June 18, 2026 and represents a direct holding. Following the trade, her reported direct ownership totals 24,703 shares.
Cardiff Oncology director Gary W. Pace bought 30,000 shares of Common Stock in an open-market transaction. The shares were purchased at a price of $1.22 per share. Following this transaction, he directly owns 1,356,376 shares of Cardiff Oncology common stock.
Cardiff Oncology, Inc. director James O. Armitage was granted stock options covering 40,565 shares of common stock. The options have an exercise price of $1.59 per share and expire on June 11, 2036. After this award, he holds 228,104 derivative securities directly.
Cardiff Oncology director Lale White received a grant of stock options. The award covers 40,565 options to buy Cardiff Oncology common stock at an exercise price of $1.59 per share.
After this grant, White holds 199,246 derivative securities directly, with the options expiring on June 11, 2036.
Cardiff Oncology director Renee P. Tannenbaum received a new stock option grant covering 40,565 shares of common stock. These options have an exercise price of $1.59 per share and expire on June 11, 2036. Following this grant, she holds 209,331 derivative securities directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
Cardiff Oncology director receives stock option grant
Cardiff Oncology, Inc. director Rodney S. Markin was granted stock options covering 40,565 shares of common stock. These options have a conversion price of $1.59 per share and relate to an equal number of underlying common shares.
Following this award, Markin holds a total of 263,430 derivative securities, reflecting his updated stock option position with the company.
Cardiff Oncology director Gary W. Pace received a new stock option grant. He was awarded options covering 40,565 shares of common stock at an exercise price of $1.59 per share. Following this grant, he holds options over a total of 228,104 shares.
Cardiff Oncology, Inc. reported the results of its Annual Meeting of Stockholders held on June 11, 2026. A quorum of 41,614,848 common shares was represented in person or by proxy.
Stockholders elected six directors to serve until the 2027 Annual Meeting, including Dr. James O. Armitage, Dr. Rodney Markin, Mani Mohindru, Ph.D., Gary W. Pace, Ph.D., Renee P. Tannenbaum, Pharm.D., and Lâle White. Each nominee received approximately 18.7–18.9 million votes in favor and no votes against, with broker non-votes around 22.3 million.
Stockholders also ratified BDO USA, P.C. as independent registered public accounting firm for the fiscal year ended December 31, 2026, with 40,239,508 votes for and 1,070,807 against. An amendment to the 2021 Equity Incentive Plan to increase the number of shares issuable to 15,150,000 was approved with 10,740,460 votes for and 8,063,520 against. In a non-binding advisory vote, compensation of the named executive officers was approved with 17,120,176 votes for and 1,772,185 against.
Cardiff Oncology, Inc. shared updated Phase 2 CRDF-004 data for its PLK1 inhibitor onvansertib in first-line RAS-mutated metastatic colorectal cancer and outlined plans for a registrational Phase 3 trial. The 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a 72% objective response rate, about 30% higher than standard FOLFIRI/bevacizumab. Median progression-free survival has not yet been reached in key onvansertib arms, while standard-of-care FOLFIRI/bevacizumab showed a median PFS of 12.22 months by investigator assessment. The company completed a successful End-of-Phase 2 FDA meeting and is proposing a ~640-patient pivotal trial with dual primary endpoints of objective response rate and progression-free survival, designed to allow accelerated approval based on response and full approval based on PFS. Safety data indicate no unexpected or new toxicities when onvansertib is added to existing chemotherapy and bevacizumab regimens.